vs

Side-by-side financial comparison of PureTech Health plc (PRTC) and Rallybio Corp (RLYB). Click either name above to swap in a different company.

Rallybio Corp is the larger business by last-quarter revenue ($222.0K vs $180.0K, roughly 1.2× PureTech Health plc). Rallybio Corp runs the higher net margin — -2636.0% vs -22820.6%, a 20184.5% gap on every dollar of revenue.

PureTech Health is an American biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange.

Rallybio Corp is a clinical-stage biotechnology company dedicated to developing transformative therapies for patients with severe, rare diseases with high unmet medical needs. Its core development pipeline targets hematologic disorders, fetal and neonatal hemolytic disease, and complement-mediated conditions, serving patient populations primarily in North America and Europe.

PRTC vs RLYB — Head-to-Head

Bigger by revenue
RLYB
RLYB
1.2× larger
RLYB
$222.0K
$180.0K
PRTC
Higher net margin
RLYB
RLYB
20184.5% more per $
RLYB
-2636.0%
-22820.6%
PRTC

Income Statement — Q4 FY2023 vs Q4 FY2025

Metric
PRTC
PRTC
RLYB
RLYB
Revenue
$180.0K
$222.0K
Net Profit
$-41.1M
$-5.9M
Gross Margin
Operating Margin
-38908.9%
-2888.3%
Net Margin
-22820.6%
-2636.0%
Revenue YoY
484.2%
Net Profit YoY
47.0%
EPS (diluted)
$-0.15
$-1.52

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRTC
PRTC
RLYB
RLYB
Q4 25
$222.0K
Q3 25
$212.0K
Q2 25
$212.0K
Q1 25
$212.0K
Q4 24
$38.0K
Q3 24
$299.0K
Q2 24
$299.0K
Q1 24
$0
Net Profit
PRTC
PRTC
RLYB
RLYB
Q4 25
$-5.9M
Q3 25
$16.0M
Q2 25
$-9.7M
Q1 25
$-9.4M
Q4 24
$-11.0M
Q3 24
$-11.5M
Q2 24
$-16.2M
Q1 24
$-19.0M
Operating Margin
PRTC
PRTC
RLYB
RLYB
Q4 25
-2888.3%
Q3 25
-3266.5%
Q2 25
-4743.9%
Q1 25
-4561.3%
Q4 24
-30547.4%
Q3 24
-4035.5%
Q2 24
-5697.3%
Q1 24
Net Margin
PRTC
PRTC
RLYB
RLYB
Q4 25
-2636.0%
Q3 25
7554.7%
Q2 25
-4576.9%
Q1 25
-4452.4%
Q4 24
-29063.2%
Q3 24
-3834.8%
Q2 24
-5430.1%
Q1 24
EPS (diluted)
PRTC
PRTC
RLYB
RLYB
Q4 25
$-1.52
Q3 25
$0.36
Q2 25
$-0.22
Q1 25
$-0.21
Q4 24
$-9.51
Q3 24
$-0.26
Q2 24
$-0.37
Q1 24
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRTC
PRTC
RLYB
RLYB
Cash + ST InvestmentsLiquidity on hand
$191.1M
$54.7M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$458.2M
$58.0M
Total Assets
$694.0M
$62.3M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRTC
PRTC
RLYB
RLYB
Q4 25
$54.7M
Q3 25
$59.3M
Q2 25
$45.7M
Q1 25
$54.5M
Q4 24
$65.5M
Q3 24
$75.1M
Q2 24
$88.6M
Q1 24
$94.2M
Stockholders' Equity
PRTC
PRTC
RLYB
RLYB
Q4 25
$58.0M
Q3 25
$63.0M
Q2 25
$46.0M
Q1 25
$54.1M
Q4 24
$61.7M
Q3 24
$70.8M
Q2 24
$80.0M
Q1 24
$89.2M
Total Assets
PRTC
PRTC
RLYB
RLYB
Q4 25
$62.3M
Q3 25
$67.7M
Q2 25
$51.0M
Q1 25
$58.0M
Q4 24
$68.1M
Q3 24
$79.0M
Q2 24
$92.4M
Q1 24
$99.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRTC
PRTC
RLYB
RLYB
Operating Cash FlowLast quarter
$-40.8M
$-4.7M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRTC
PRTC
RLYB
RLYB
Q4 25
$-4.7M
Q3 25
$-6.5M
Q2 25
$-8.4M
Q1 25
$-10.2M
Q4 24
$-9.9M
Q3 24
$-13.5M
Q2 24
$-10.4M
Q1 24
$-15.5M
Cash Conversion
PRTC
PRTC
RLYB
RLYB
Q4 25
Q3 25
-0.41×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons